An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial

被引：0
|
作者：
Liu, Joyce [1 ]
Gunderson, Camille [2 ]
Hendrickson, Andrea Wahner [3 ]
Ratner, Elena [4 ]
Diver, Elisabeth [5 ]
Moroney, John [6 ]
Arend, Rebecca C. [7 ]
Louie-Gao, Melinda [8 ]
Wang, Sarah [8 ]
Luptakova, Katarina [8 ]
Konecny, Gottfried E. [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Mayo Clin, Dept Oncol, Rochester, MN USA
[4] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[5] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA
[6] Univ Chicago Med, Dept Obstet & Gynecol, Chicago, IL USA
[7] Univ Alabama Birmingham, Obstet & Gynecol, Birmingham, AL USA
[8] TESARO Inc, Waltham, MA USA
[9] Univ Calif Los Angeles, Med Ctr, Dept Med, Santa Monica, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
    Verhaar-Langereis, M
    Karakus, A
    Van Eijkeren, M
    Voest, E
    Witteveen, E
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 65 - 70
  • [32] Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
    Thejeswar Nakka
    Luxitaa Goenka
    Biswajit Dubashi
    Smita Kayal
    Jayanthi Mathaiyan
    Deepak Barathi
    Narendran Krishnamoorthy
    Divya Bala Thumaty
    Sindhu Dahagama
    Prasanth Ganesan
    Medical Oncology, 39
  • [33] Relacorilant plus Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
    Colombo, Nicoletta
    Van Gorp, Toon
    Matulonis, Ursula A.
    Oaknin, Ana
    Grisham, Rachel N.
    Fleming, Gini F.
    Olawaiye, Alexander B.
    Nguyen, Dorothy D.
    Greenstein, Andrew E.
    Custodio, Joseph M.
    Pashova, Hristina I.
    Tudor, Iulia C.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4779 - +
  • [34] Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
    Thejeswar, N.
    Goenka, L.
    Dubashi, B.
    Kayal, S.
    Jayanthi, M.
    Barathi, D.
    Ganesan, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1510 - S1510
  • [35] Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician's choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
    Lorusso, D.
    Musacchio, L.
    Pignata, S.
    Braicu, E. I.
    Cibula, D.
    Colombo, N.
    Frenel, J-S.
    Zagouri, F.
    Carbone, V.
    Ghizzoni, V.
    Giolitto, S.
    Giudice, E.
    Landolfo, C.
    Perri, M. T.
    Ricci, C.
    Salutari, V.
    Scambia, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S768 - S769
  • [36] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
    Hamanishi, Junzo
    Takeshima, Nobuhiro
    Katsumata, Noriyuki
    Ushijima, Kimio
    Kimura, Tadashi
    Takeuchi, Satoshi
    Matsumoto, Koji
    Ito, Kimihiko
    Mandai, Masaki
    Nakai, Hidekatsu
    Sakuragi, Noriaki
    Watari, Hidemichi
    Takahashi, Nobutaka
    Kato, Hidenori
    Hasegawa, Kosei
    Yonemori, Kan
    Mizuno, Mika
    Takehara, Kazuhiro
    Niikura, Hitoshi
    Sawasaki, Takashi
    Nakao, Sari
    Saito, Toshiaki
    Enomoto, Takayuki
    Nagase, Satoru
    Suzuki, Nao
    Matsumoto, Takashi
    Kondo, Eiji
    Sonoda, Kenzo
    Aihara, Satomi
    Aoki, Yoichi
    Okamoto, Aikou
    Takano, Hirokuni
    Kobayashi, Hiroshi
    Kato, Hisamori
    Terai, Yoshito
    Takazawa, Akira
    Takahashi, Yusuke
    Namba, Yoshinobu
    Aoki, Daisuke
    Fujiwara, Keiichi
    Sugiyama, Toru
    Konishi, Ikuo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (33) : 3671 - +
  • [37] Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial
    Gao, Q.
    Zhang, H.
    Zheng, H.
    An, R.
    Jiang, J.
    Li, Q.
    Chen, Z.
    Li, J.
    Li, G.
    Li, R.
    Xie, R.
    Ma, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S565 - S565
  • [38] Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
    Chong, W. Q.
    Low, J. L.
    Sooi, K.
    Soo, R. A.
    Le, C.
    Teo, H. L.
    Samol, J.
    Goh, G.
    Kong, L. R.
    DasGupta, R.
    Chia, S.
    Wong, R.
    Gopinathan, A.
    Tay, J. K.
    Eu, D.
    Tsang, R.
    Loh, K-S.
    Tai, B. C.
    Lim, Y. C.
    Goh, B-C.
    ANNALS OF ONCOLOGY, 2024, 35 : S614 - S614
  • [39] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [40] Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)
    Pujade-Lauraine, Eric
    Weber, Beatrice E.
    Ray-Coquard, Isabelle
    Vergote, Ignace
    Selle, Frederic
    Del Campo, Jose Maria
    Sufliarsky, Jozef
    Tschoepe, Inga
    Chesa, Pilar Garin
    Nazabadioko, Serge
    Pilz, Korinna
    Joly, Florence
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345